Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second-line chemotherapy in patients with small cell lung cancer.

Motoki Sekikawa,Haruyasu Murakami,Meiko Morita,Kosei Doshita,Keita Miura,Hiroaki Kodama,Noboru Morikawa,Yuko Iida,Nobuaki Mamesaya,Haruki Kobayashi,Ryo Ko,Kazushige Wakuda,Akira Ono,Hirotsugu Kenmotsu,Tateaki Naito,Hirofumi Chiba,Toshiaki Takahashi

Thoracic cancer（2023）

引用 0|浏览9

暂无评分

摘要

AMR with P-PEG as second-line chemotherapy for SCLC reduced the incidence of FN at a maintained AMR dose intensity and was associated with favorable tumor responses and survival outcomes. P-PEG should be considered for patients treated with AMR for SCLC including refractory relapsed SCLC.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要